BMY: Bristol-Myers Squibb Company - Summary | Jitta

Bristol-Myers Squibb Company

NYSE:BMY

Price
$66.83
Loss Chance
41.6%
6.08JITTA SCORE
33.61%Over Jitta Line
Jitta Ranking
169 / 1,017
2,007 / 4,522
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (53)
Recent Business Performance (33)
Financial Strength (67)
Return to Shareholders (62)
Competitive Advantage (71)
Jitta Signs
Interest Coverage RatioVery Good
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning decline from 2015-2020
Operating MarginDeclined
Debt LevelHigh Long Term Debt
Recent Business PerformanceEarning decline 66.29% in the last year
Key Stats
Jitta Score
Jitta Line
6.08
33.61%
2.02
119.55%
2.28
> 1,000%
Pharmaceuticals
5.15
0.12%
3.62
10.98%
4.51
44.16%
COMPANY DESCRIPTION
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; and DarwinHealth, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.